Literature DB >> 2569411

Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat.

B Glenthøj1, R Hemmingsen.   

Abstract

Rats were treated either discontinuously or continuously with haloperidol. Only discontinuous treatment caused a long-lasting abnormal rise in the number of mouth movements. After termination of medication the animals were kindled electrically in the nucleus amygdala. The results suggest cross-sensitivity between discontinuous neuroleptic treatment and amygdala kindling. Our results are consistent with the hypothesis of a kindling-like sensitization to the dyskinetic-inducing side-effects of neuroleptic drugs following intermittent antidopaminergic treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569411     DOI: 10.1016/0014-2999(89)90486-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Drug-induced oral dyskinesias in rats after traditional and new neuroleptics.

Authors:  T Kakigi; X M Gao; C A Tamminga
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Spontaneous orofacial movements in rodents induced by long-term neuroleptic administration: a second opinion.

Authors:  G Ellison
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 3.  Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.

Authors:  J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.

Authors:  B Glenthøj
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  High frequency oral movements induced by long-term administration of amperozide but not FG5803 in rats.

Authors:  U Liminga; P E Andren; L S Ohlund; L M Gunne
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.